Skip to Content
Merck

Enhanced activation of human NK cells by drug-exposed hepatocytes.

Archives of toxicology (2020-02-16)
Frank Fasbender, Martin Obholzer, Sarah Metzler, Regina Stöber, Jan G Hengstler, Carsten Watzl
ABSTRACT

Drug-induced liver injury (DILI) represents one of the major causes why drugs have to be withdrawn from the market. In this study, we describe a new interaction between drug-exposed hepatocytes and natural killer (NK) cells. In a previous genome-wide expression analysis of primary human hepatocytes that had been exposed to clinically relevant concentrations of 148 drugs, we found that several activating ligands for NK cell receptors were regulated by various drugs (e.g., valproic acid, ketoconazole, promethazine, isoniazid). Especially expression of the activating NKG2D ligands (MICA, MICB and ULBPs) and the NKp30 ligand B7-H6 were upregulated in primary human hepatocytes upon exposure to many different drugs. Using the human hepatocyte cell lines Huh7 and HepG2, we confirmed that protein levels of activating NK cell ligands were elevated after drug exposure. Hepatocyte cell lines or primary human hepatocytes co-cultivated with NK cells caused enhanced NK cell activation after pretreatment with drugs at in vivo relevant concentrations compared to solvent controls. Enhanced NK cell activation was evident by increased cytotoxicity against hepatocytes and interferon (IFN)-γ production. NK cell activation could be blocked by specific antibodies against activating NK cell receptors. These data support the hypothesis that NK cells can modulate drug-induced liver injury by direct interaction with hepatocytes resulting in cytotoxicity and IFN-γ production.

MATERIALS
Product Number
Brand
Product Description

Supelco
Valproic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Acetylsalicylic acid, ≥99.0%
Sigma-Aldrich
Promethazine hydrochloride
Supelco
Isoniazid, analytical standard, ≥99% (TLC)
Sigma-Aldrich
Ketoconazole, 99.0-101.0% (EP, titration)